Efficacy and safety of ARM-P (Anti-reflux mucoplasty) for drug-resistant and dependent gastroesophageal reflux disease (GERD)

Yamamoto Kazuki0 个研究点目标入组 93 人开始时间: 2023年7月14日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•The study will include patients with drug-resistant/dependent gastroesophageal reflux disease (GERD) who meet the following indication criteria
•1. Individuals who are scheduled for treatment with anti-reflux mucosal ablation (ARMS).
•2. Individuals who have provided written consent to participate in this study. In the case of individuals under 18 years of age, written consent from a legal representative is also required.

•1. Individuals with significant sliding-type hiatal hernia.
•2. Individuals with impaired esophageal motility.
•3. Pregnant individuals.
•4. Individuals with psychiatric or neurological disorders.
•5. Individuals with severe respiratory diseases (such as chronic obstructive pulmonary disease, hypoxemia, home oxygen therapy, etc.).
•6. Individuals with severe underlying conditions (severe heart failure, renal failure, liver failure).
•7. Any other individuals deemed inappropriate for participation by the principal investigator or co-investigators.

发起方

Yamamoto Kazuki